Beyond Truvada – what is the future of PrEP?
Bictegravir matches dolutegravir in first-line treatment
Substantial gaps in PrEP care continuum for trans women in San Francisco
Neural tube defects and integrase inhibitors: studies show no further evidence of increased risk
Two-drug protease inhibitor treatment as effective as three-drug treatment – and fewer stop due to side-effects
Boston HIV clinic sees 90% reduction in infections in people being prescribed PrEP
PrEP providers and communicators should stop talking about ‘risk’
First large HIV prevention trial using antibodies will probably not be the last
Behind the scenes at European Testing Week